The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Open Access
- 1 January 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (1), 76-79
- https://doi.org/10.1158/1055-9965.epi-05-0709
Abstract
This is by far the largest study of its kind to date, and further suggests that AIB1 does not play a substantial role in modifying the phenotype of BRCA1 and BRCA2 carriers. The AIB1 gene encodes the AIB1/SRC-3 steroid hormone receptor coactivator, and amplification of the gene and/or protein occurs in breast and ovarian tumors. A CAG/CAA repeat length polymorphism encodes a stretch of 17 to 29 glutamines in the HR-interacting carboxyl-terminal region of the protein which is somatically unstable in tumor tissues and cell lines. There is conflicting evidence regarding the role of this polymorphism as a modifier of breast cancer risk in BRCA1 and BRCA2 carriers. To further evaluate the evidence for an association between AIB1 glutamine repeat length and breast cancer risk in BRCA1 and BRCA2 mutation carriers, we have genotyped this polymorphism in 1,090 BRCA1 and 661 BRCA2 mutation carriers from Australia, Europe, and North America. There was no evidence for an increased risk associated with AIB1 glutamine repeat length. Given the large sample size, with more than adequate power to detect previously reported effects, we conclude that the AIB1 glutamine repeat does not substantially modify risk of breast cancer in BRCA1 and BRCA2 mutation carriers. (Cancer Epidemiol Biomarkers Prev 2006;15(1):76–9)Keywords
This publication has 12 references indexed in Scilit:
- Breast cancer risk inBRCA1 andBRCA2 mutation carriers and polyglutamine repeat length in theAIB1 geneInternational Journal of Cancer, 2005
- Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer familiesHuman Genetics, 2005
- A weighted cohort approach for analysing factors modifying disease risks in carriers of high‐risk susceptibility genesGenetic Epidemiology, 2005
- The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian womenBreast Cancer Research, 2005
- The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancerBreast Cancer Research, 2004
- Somatic instability of the DNA sequences encoding the polymorphic polyglutamine tract of the AIB1 geneJournal of Medical Genetics, 2003
- Polyglutamine repeat length in theAIB1 gene modifies breast cancer susceptibility inBRCA1 carriersInternational Journal of Cancer, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesAmerican Journal of Human Genetics, 2003
- Gene Amplification and Expression of the Steroid Receptor Coactivator SRC3 (AIB1) in Sporadic Breast and Endometrial CarcinomasHormone and Metabolic Research, 2001
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997